$69.100
+0.290 (+0.42%)收盘时
SLGL 资讯
SLGL 事件
Sol-Gel Reports Q1 Revenue of $108,000
Reports Q1 revenue $108,000 vs. $1.03M last year. Mori Arkin, executive chairman of Sol-Gel, stated: "The first quarter of 2026 was a period of substantial progress on every front that matters to Sol-Gel. The Notice of Allowance extending the exclusivity of patidegib until 2044 marks a major milestone in the value creation of SGT-610 and Sol-Gel as a company. In parallel, the successful completion of our oversubscribed offering, with broad participation from leading healthcare specialist investors, is expected to provide Sol-Gel with the financial resources to support operations into 2028, allowing us to execute our Phase 3 program of SGT-610 through top-line readout and to support its pre-commercialization activities."
TD Cowen and LifeSci Capital Jointly Manage Offering
TD Cowen and LifeSci Capital are acting as joint book running managers for the offering.
Sol Gel Technologies Trading Halted
Sol Gel Technologies trading halted, volatility trading pause
Sol-Gel Technologies Halts SGT-210 Development for Darier Disease
Sol-Gel Technologies provided an update following the unblinding of clinical data from its vehicle-controlled proof-of-concept Phase 1b study of SGT-210 on Darier disease. Following unblinding, the data from the vehicle-controlled Phase 1b proof-of-concept study did not show differentiation between SGT-210 and vehicle on the study's efficacy assessments. Mori Arkin, Executive Chairman of Sol-Gel, stated: "After unblinding the clinical data from our trial, the study did not demonstrate a signal of superiority of active treatment versus vehicle, and we have therefore decided not to advance to the next stage of development in this indication. We intend to pursue very small, low-cost feasibility studies in other areas of unmet medical need where the mechanistic rationale for SGT-210 is strong. We continue to prioritize the successful completion of our Phase 3 program of SGT-610 in Gorlin syndrome and preparatory activities supporting a potential Phase 3 program in high-frequency BCC, subject to successful completion of the Gorlin Phase 3 trial."
Sol-Gel Technologies announces Q3 earnings per share of $2.13 compared to a loss of 13 cents last year.
Reports Q3 revenue $400k vs $5.4M last year. Mori Arkin, Executive Chairman of Sol-Gel, stated: "Sol-Gel continued to make steady progress in the third quarter as we advance our late-stage pipeline in dermatologic rare diseases. Our pivotal Phase 3 trial of SGT-610 for Gorlin syndrome is ongoing, and we remain focused on executing this study to deliver top-line results in the fourth quarter of 2026. We are particularly excited about the opportunity of at least doubling the potential of this important drug by adding the unmet need of high-frequency BCC."
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。